Member Info for Cebo-456

Mccadder - it would be 7million at 5p if you include the open offer - not guaranteed they will do this but todays RnS just about guarantees that the SP will drop towards the 5p level, even before they announce any raise.

A new CPR, really ffs, a new CPR will not prove anyone was lying or telling the truth - any CPR results/conclusions/estimates will always depend on what figures and info you put in, it will cost $millions, prove nothing and benefit no-one at all. - CRS think they know what reserves and resources Hur hold (hence buying as much as they can), any potential Suitors/partner who would ussualy ask for a CPR will have already made up their mind about Hurricanes acerage, most will have had teams run the rule over the data years ago and will still be tracking them.
The only other real purpose of a CPR is for RBL, unlikely that they will go down this route.

More interesting is the value of the tax credits and very soon the Company could be in a position of having no debt at all, cash in the bank but with Tax Credits worth more than the MC - whilst hopefully still producing nearly a million $ worth of oil per day.

A new CPR, really ffs, a new will not prove anyone was lying or telling the truth - any CPR results/conclusions/estimates will always depend on what figures and info you put in, it will cost $millions, prove nothing and benefit no-one at all. - CRS think they know what reserves and resources Hur hold (hence buying as much as they can), any potential Suitors/partner who would ussualy ask for a CPR will have already made up their mind about Hurricanes acerage, most will have had teams run the rule over the data yeats ago and will still be tracking them.
The only other real purpose of a CPR is for RBL, unlikely that they will go down this route.

More interesting is the value of the tax credits and very soon the Company could be in a position of having no debt at all, cash in the bank but with Tax Credits worth more than the MC - whilst hipefully still producing nearly a million $ worth of oil per day.

*morning star

Youzlez - right name, but the wrong Juan. :-) I believe the proposed chap has been involved with CRS for more than a decade, and ex moving star analyst before that.

Juan Morera is already employed by CRS advisors - so a good and exciting appointment but one that needs a little clarification. Is Crystal Amber officially taking a seat at the table - and as such they will be rightly privy to inside info but with all the restrictions to their trading that comes with being officially inside.
Interesting times.

TopCat, the BoD do not really give a toss about the current share price, in fact the CE mark coming this week may not have been welcome at Alva if the plan was to get a placing away - without it being at a huge discount

However it may now also be a case that II's would be more willing to invest with the CE mark.
Tricky one to call - if a placing comes then it suggests that no large orders are in the pipeline and this will spook the market - if they announce Sales then they won't get a placing away as the SP will rise - but with decent sales then we may not need to raise money.

Next week should be interesting.

Staz, forward selling can and does still happen, rule 120.3 covers it, as well as guidance to rule 1400. Cornhill got fined around £300k a few years ago when the forward sold shares in an Oil company's (can't remember the name) after the placing was voted down by the shareholders. They were fined, not for forward selling, but because they never had procedures in place to cover the possibility of a no-vote at the GM. Obviously google it for full details.

I suspect that by the wording of the RNS, the ODX board would have preferred to get the raise away before the CE news came out yedterday - as any raise now would again be at a discount ti current price after the SP movement this last couple of days -
On the flip side, if they are confident that the test can be sold in Europe from the 01st April then they should have no need at all to raise money.

Interesting times.

OdX are "co-exibiting" with their distributor in Dubai next week in any investors want to attend. - 24-27 Jan.

"Conclude" - if investors don't pick up on this then maybe they shouldn't be invested.
Getting close to the big one.

Baggins, Nickel prices have more than doubles from below < 10k/tonne to above 22k/tonne - so they have become hugely lucrative since NN were the operator. Nickel demand for 2022 onwards is projected to go go through the roof, along with the price.
But then you knew that anyway.
I suspect that this RNS is about getting their house in order ready for the long awaiting sale/s.

There may be a lot of investors switched off for the week and missed the RNS, may be a slow burner until Retail investors read and understand the news - another huge step forward in my opinion.

Wishfull thinking perhaps - do we know - once the test has been tweaked then do we need a full evaluation of the "new" test/product and do Avacta need to resubmit or amend the documents to gain its CE and HUA status's.

* ... all else is just noise

Disappointing but not the end. TT will need tweaking and new tests verifying once Avacta sort them out. More disappointing is news that the other TT is still a couple of months from completion (end of Q1).
IMO, Those that offloaded first thing did well (I never) those that ride out the storm and/or buy in at the bottom (which I am guessing will be Wed afternoon ish) will do well. All is is just noise.
GLA

GLR, I have done extensive research on both Companies, watched every presentation/interview and read every RNS, so more than happy that I have enough info to make the right trading decisions (for me). There are enough pathetic muppets on those boards that think that sticking the boot into one company will somehow benefit the other without me joining in- not my game thanks.

GLR, I have done extensive research on both Companies, watched every presentation/interview and read every RNS, so more than happy that I have enough info to make the right trading decisions (for me). There are enough pathetic muppets on those boards that think that sticking the boot into one company will somehow benefit the other without me joing in- not my game thanks.

Not sure that you can compare both companies - ODX have have their CD4, Food Intolerance / Glabal Health testing to underpin a lot of their marketcap. I am invested in both, both are still high risk still with potential very high reward, and hopefully both will do very well eventually.
I do agree that Abdx at the minute looks a better bet for a steeper rise on news due to its smaller MC and simpler model, news on TT with the Avacta test being completed will get this moving, but it will take orders to really get the boosters on.
Fingers crossed that the wait isn't too long for both companies.

Very good chance that this is still a closed period for director dealings - not so much due to Val201 but because of the NDAs in place with the Japanese Pharma and the University. Also any iminent update on CovidCM201 or 401 that we do not know about would prevent any directors from buying as well as another compound evaluation announcement that may be close.
I believe that there is a good chance that we will see the signature for Val201 shortly - TheoremRx will want/need the funding wrapped up long before they start the trials and although their Scientist's will be talking to potential hospitals with Suzy, nothing can be agreed until they have the funds in place and have signed the agreement.
Those wanting directors dealing are likely looking for short term trading opportunities, and good luck to them, but if you do your research the real value will be those holding and letting the BoD do their job, not pampering to Retail investors by buying token amounts of shares.

Ignore the Fools on here - Theorem only, in my opinion, will be looking to raise 15-20$mill - relatively small xhange across the pond.
They could always raise another $60mil, build a stake and try to take Val out in it entirity. :-) - it would save them a lot of dosh in the longer term.